Garlic, onions and cardiovascular risk factors. A review of the evidence from human experiments with emphasis on commercially available preparations [see comments]
- 1 November 1989
- journal article
- research article
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 28 (5) , 535-544
- https://doi.org/10.1111/j.1365-2125.1989.tb03539.x
Abstract
1. Claims for beneficial effects on cholesterol levels, fibrinolytic activity, and platelet aggregation are attributed both to fresh garlic and onions (or their extracts) and to commercially available preparations. 2. Regarding fresh garlic, the claims have been confirmed, but so far only at very high dosages. 3. For onions and commercially available supplements contradictory results have been reported. 4. All published trials showed severe methodological shortcomings. Some trials were not randomized and/or not blinded whilst this was possible, and in only one of every three studies more than 25 patients participated in each treatment group. In no trial was prognostic comparability of the treatment and the control groups ascertained. At the moment there is inadequate scientific justification for garlic supplementation.This publication has 38 references indexed in Scilit:
- INHIBITORS OF CYCLO-OXYGENASE AND LIPOXYGENASE IN ONIONSThe Lancet, 1988
- NEW INHIBITOR OF PLATELET AGGREGATION IN ONION OILThe Lancet, 1988
- Identification of alliin, a constituent of Allium cepa with an inhibitory effect on platelet aggregationPhytochemistry, 1985
- Garlic and blood lipids.BMJ, 1985
- The Chemistry of Garlic and OnionsScientific American, 1985
- Comparative effect of clofibrate, garlic and onion on alimentary hyperlipemiaAtherosclerosis, 1981
- PLATELET AGGREGATION INHIBITOR IN GARLICThe Lancet, 1981
- . OR GARLICThe Lancet, 1979
- Controlled trial of the effect of cycloalliin on the fibrinolytic activity of venous bloodAtherosclerosis, 1977
- Effect of the essential oils of garlic and onion on alimentary hyperlipemiaAtherosclerosis, 1975